Institution · Aeras

Most cited papers from Aeras

Aeras

What are the most cited papers from Aeras?

The most cited paper from Aeras is "Tuberculosis" (Madhukar Pai, Marcel A. Behr, David W. Dowdy et al., 2016), with 1,305 citations. Next come "Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial" (1,060) and "Prevention of M. tuberculosis Infection with H4:IC31 Vaccine or BCG Revaccination" (675).

Published TypeFieldAccessAuthorsCitations

Showing 50 of 60 papers. Every paper with more than 76 citations is listed.

Most cited papers, sortable by citations and release date
#	Paper
1	Tuberculosis Madhukar Pai, Marcel A. Behr, David W. Dowdy et al. · Nature Reviews Disease Primers Review	27 Oct 2016	1,305
2	Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial Michele D. Tameris, Mark Hatherill, Bernard Landry et al. · The Lancet Open access	4 Feb 2013	1,060
3	Prevention of M. tuberculosis Infection with H4:IC31 Vaccine or BCG Revaccination Elisa Nemes et al. · New England Journal of Medicine Open access	11 Jul 2018	675
4	Prevention of tuberculosis in macaques after intravenous BCG immunization Patricia A. Darrah et al. · Nature Open access	2020	619
5	Phase 2b Controlled Trial of M72/AS01 E Vaccine to Prevent Tuberculosis Olivier Van Der Meeren et al. · New England Journal of Medicine Open access	25 Sep 2018	425
6	Specific T Cell Frequency and Cytokine Expression Profile Do Not Correlate with Protection against Tuberculosis after Bacillus Calmette-Guérin Vaccination of Newborns Benjamin M. N. Kagina, Brian Abel, Thomas J. Scriba et al. · American Journal of Respiratory and Critical Care Medicine Open access	17 Jun 2010	409
7	Evaluation of Tuberculosis Diagnostics in Children: 1. Proposed Clinical Case Definitions for Classification of Intrathoracic Tuberculosis Disease. Consensus From an Expert Panel Stephen M. Graham et al. · The Journal of Infectious Diseases Open access	24 Mar 2012	330
8	Advances in tuberculosis vaccine strategies Yasir A. W. Skeiky, JERALD C. SADOFF · Nature Reviews Microbiology Review	18 May 2006	300
9	T-cell activation is an immune correlate of risk in BCG vaccinated infants Helen A. Fletcher et al. · Nature Communications Open access	12 Apr 2016	277
10	Prevention of tuberculosis in rhesus macaques by a cytomegalovirus-based vaccine Scott G. Hansen et al. · Nature Medicine Open access	15 Jan 2018	273
11	A novel liposomal adjuvant system, CAF01, promotes long-lived Mycobacterium tuberculosis-specific T-cell responses in human Jaap T. van Dissel, Simone A. Joosten, Soren Tetens Hoff et al. · Vaccine Open access	30 Oct 2014	247
12	Latent tuberculosis infection in rural China: baseline results of a population-based, multicentre, prospective cohort study Lei Gao et al. · The Lancet Infectious Diseases	10 Feb 2015	234
13	The Novel Tuberculosis Vaccine, AERAS-402, Induces Robust and Polyfunctional CD4+ and CD8+ T Cells in Adults Brian Abel et al. · American Journal of Respiratory and Critical Care Medicine Open access	18 Feb 2010	227
14	Disruption of the ESX‐5 system of Mycobacterium tuberculosis causes loss of PPE protein secretion, reduction of cell wall integrity and strong attenuation Daria Bottai, Mariagrazia Di Luca, Laleh Majlessi et al. · Molecular Microbiology Open access	20 Feb 2012	216
15	First-in-human trial of the post-exposure tuberculosis vaccine H56:IC31 in Mycobacterium tuberculosis infected and non-infected healthy adults Angelique Kany Kany Luabeya et al. · Vaccine	19 Jun 2015	202
16	A New Recombinant Bacille Calmette‐Guérin Vaccine Safely Induces Significantly Enhanced Tuberculosis‐Specific Immunity in Human Volunteers Daniel Fredric Hoft, Azra Blazevic, Getahun Abate et al. · The Journal of Infectious Diseases Open access	22 Sep 2008	179
17	Protective Immune Responses to a Recombinant Adenovirus Type 35 Tuberculosis Vaccine in Two Mouse Strains: CD4 and CD8 T-Cell Epitope Mapping and Role of Gamma Interferon Katarina Radošević, Catharina W. Wieland, Ariane Rodrı́guez et al. · Infection and Immunity Open access	26 May 2007	178
18	RISK6, a 6-gene transcriptomic signature of TB disease risk, diagnosis and treatment response Adam Penn‐Nicholson et al. · Scientific Reports Open access269 authors	25 May 2020	177
19	Tuberculosis Susceptibility and Vaccine Protection Are Independently Controlled by Host Genotype Clare M. Smith, Megan K. Proulx, Andrew J. Olive et al. · mBio Open access	20 Sep 2016	173
20	Optimization and Interpretation of Serial QuantiFERON Testing to Measure Acquisition of Mycobacterium tuberculosis Infection Elisa Nemes et al. · American Journal of Respiratory and Critical Care Medicine Open access	24 Jul 2017	169
21	Safety, immunogenicity, and efficacy of the candidate tuberculosis vaccine MVA85A in healthy adults infected with HIV-1: a randomised, placebo-controlled, phase 2 trial B Ndiaye et al. · The Lancet Respiratory Medicine Open access	25 Feb 2015	169
22	The TLR-4 agonist adjuvant, GLA-SE, improves magnitude and quality of immune responses elicited by the ID93 tuberculosis vaccine: first-in-human trial Rhea N. Coler et al. · npj Vaccines Open access	4 Jul 2018	166
23	Metabolite changes in blood predict the onset of tuberculosis January Mikolaj Weiner et al. · Nature Communications Open access106 authors	30 Nov 2018	162
24	Tuberculosis Vaccines and Prevention of Infection Thomas R. Hawn, Tracey A. Day, Thomas J. Scriba et al. · Microbiology and Molecular Biology Reviews ReviewOpen access	26 Nov 2014	158
25	Novel recombinant BCG expressing perfringolysin O and the over-expression of key immunodominant antigens; pre-clinical characterization, safety and protection against challenge with Mycobacterium tuberculosis Ronggai Sun, Yasir A. W. Skeiky, Angelo A. Izzo et al. · Vaccine Open access	3 Jun 2009	158
26	Safety and immunogenicity of the novel tuberculosis vaccine ID93 + GLA-SE in BCG-vaccinated healthy adults in South Africa: a randomised, double-blind, placebo-controlled phase 1 trial Adam Penn‐Nicholson, Michele D. Tameris, Erica Smit et al. · The Lancet Respiratory Medicine	23 Mar 2018	154
27	Serial QuantiFERON testing and tuberculosis disease risk among young children: an observational cohort study Jason Randolph Andrews, Elisa Nemes, Michele D. Tameris et al. · The Lancet Respiratory Medicine Open access	16 Feb 2017	150
28	Immunization by a bacterial aerosol Lucila Garcia‐Contreras, Yun-Ling Wong, Pavan Muttil et al. · Proceedings of the National Academy of Sciences Open access	14 Mar 2008	143
29	Association of Human Antibodies to Arabinomannan With Enhanced Mycobacterial Opsonophagocytosis and Intracellular Growth Reduction Tingting Chen, Caroline Blanc, Anke Z. Eder et al. · The Journal of Infectious Diseases Open access	7 Apr 2016	141
30	STING-Activating Adjuvants Elicit a Th17 Immune Response and Protect against Mycobacterium tuberculosis Infection Erik S. Van Dis, Kimberly M. Sogi, Chris S. Rae et al. · Cell Reports Open access	May 2018	136
31	Whole genome identification of Mycobacterium tuberculosisvaccine candidates by comprehensive data mining and bioinformatic analyses Anat Zvi, Naomi Ariel, John P. Fulkerson et al. · BMC Medical Genomics Open access	28 May 2008	135
32	Transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to animals: an updated review Sina Salajegheh Tazerji et al. · Journal of Translational Medicine Open access	21 Sep 2020	131
33	Healthcare associated infection and its risk factors among patients admitted to a tertiary hospital in Ethiopia: longitudinal study Solomon Ali, Melkamu Birhane, Sisay Bekele et al. · Antimicrobial Resistance and Infection Control Open access	5 Jan 2018	130
34	The Tuberculin Skin Test versus QuantiFERON TB Gold® in Predicting Tuberculosis Disease in an Adolescent Cohort Study in South Africa Hassan Mahomed, Tony Hawkridge, Suzanne Verver et al. · PLoS ONE Open access	29 Mar 2011	129
35	Dose Optimization of H56:IC31 Vaccine for Tuberculosis-Endemic Populations. A Double-Blind, Placebo-controlled, Dose-Selection Trial Sara Suliman, Angelique Kany Kany Luabeya, Hennie D. Geldenhuys et al. · American Journal of Respiratory and Critical Care Medicine	9 Aug 2018	121
36	Induction and Regulation of T-Cell Immunity by the Novel Tuberculosis Vaccine M72/AS01 in South African Adults Cheryl L. Day et al. · American Journal of Respiratory and Critical Care Medicine Open access	10 Jan 2013	121
37	New live mycobacterial vaccines: the Geneva consensus on essential steps towards clinical development Arun T. Kamath, Uli Fruth, Michael J. Brennan et al. · Vaccine Open access	4 Apr 2005	120
38	Progress and challenges in TB vaccine development Gérald Voss, Danilo R. Casimiro, Olivier Neyrolles et al. · F1000Research Open access	16 Feb 2018	119
39	Tuberculosis Vaccines: A Strategic Blueprint for the Next Decade Michael J. Brennan, Jelle E. R. Thole · Tuberculosis	Mar 2012	118
40	The Enigmatic PE/PPE Multigene Family of Mycobacteria and Tuberculosis Vaccination Michael J. Brennan · Infection and Immunity Open access	27 Mar 2017	116
41	Efficacy of percutaneous versus intradermal BCG in the prevention of tuberculosis in South African infants: randomised trial Anthony Hawkridge, Mark Hatherill, Francesca Little et al. · BMJ Open access	13 Nov 2008	115
42	Emergence of high drug resistant bacterial isolates from patients with health care associated infections at Jimma University medical center: a cross sectional study Mulatu Gashaw, Melkamu Berhane, Sisay Bekele et al. · Antimicrobial Resistance and Infection Control Open access	19 Nov 2018	108
43	T cell receptor repertoires associated with control and disease progression following Mycobacterium tuberculosis infection Munyaradzi Musvosvi et al. · Nature Medicine Open access148 authors	2023	107
44	Drug-resistant TB: deadly, costly and in need of a vaccine Janna Manjelievskaia, Dara Erck, Samina Piracha et al. · Transactions of the Royal Society of Tropical Medicine and Hygiene Open access	16 Feb 2016	101
45	Heat Shock Proteins: Stimulators of Innate and Acquired Immunity Camilo A.L.S. Colaco, Christopher R. Bailey, Kenneth Barry Walker et al. · BioMed Research International Open access	2013	97
46	rBCG Induces Strong Antigen-Specific T Cell Responses in Rhesus Macaques in a Prime-Boost Setting with an Adenovirus 35 Tuberculosis Vaccine Vector Isabelle Pinheiro Amaro de Magalhães, Donata R. Sizemore, Raija K.S. Ahmed et al. · PLoS ONE Open access	21 Nov 2008	96
47	Novel replication-incompetent adenoviral B-group vectors: high vector stability and yield in PER.C6 cells Menzo J E Havenga, Ronald Vogels, David Zuijdgeest et al. · Journal of General Virology	17 Jul 2006	95
48	Induced sputum or gastric lavage for community-based diagnosis of childhood pulmonary tuberculosis? M Hatherill, Tony Hawkridge, Heather Joy Zar et al. · Archives of Disease in Childhood	Oct 2008	94
49	A recombinant adenovirus expressing immunodominant TB antigens can significantly enhance BCG-induced human immunity Daniel Fredric Hoft, Azra Blazevic, Jaime Stanley et al. · Vaccine	31 Jan 2012	94
50	HIV‐1 Infection in Infants Severely Impairs the Immune Response Induced by Bacille Calmette‐Guérin Vaccine Nazma Mansoor, Thomas J. Scriba, Marwou de Kock et al. · The Journal of Infectious Diseases Open access	23 Feb 2009	93

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.